Back to results
US 2012/0251493 A1Published application
Novel macrocyclic inhibitors of hepatitis c virus replication
OwnerScott D. Seiwert, John B. Nicholas +2inventors
InventorsScott D. Seiwert, John B. Nicholas, Brad Buckman, Vladimir Serebryany
Life of this patent
Estimating the term…
Abstract
The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Claims46
A compound having the structure of Formula (I):
- or a pharmaceutically acceptable salt or prodrug thereof,
- wherein W1, W2, W2 and W4 are independently -D or —H, provided that at least one of W1, W2, W2 and W4 is -D;
- R1 is selected from the group consisting of —C(O)OR1e, optionally substituted heteroaryl, and aryl optionally substituted with one or more substituents each independently selected from the group consisting of halo, amino, C1-6 alkyl optionally substituted with up to 5 fluoro, C1-6 alkoxy optionally substituted with up to 5 fluoro, C2-6 alkenyl, C2-6 alkynyl, —C(O)NR1aR1b, —NHC(O)NR1aR1b, —C(O)OR1c, and heteroaryl;
- R1e is selected from the group consisting of t-butyl, cycloalkyl, and heterocyclyl;
- R1a and R1b are taken together with the nitrogen to which they are attached to form piperazinyl or morpholinyl, each optionally substituted with one or more substituents independently selected from optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —C(O)OR1c, —C(O)R1d, optionally substituted aryl, and optionally substituted heteroaryl;
- R1c and R1d are each separately selected from the group consisting of —H, C1-4 alkoxy, C1-6 alkyl, C3-7 cycloalkyl, aryl, arylalkyl and heteroaryl;
- R3 is —OH, —NHS(O)2R3a, —NHS(O)2OR3a or —NHS(O)2NR3bR3c;
- where R1a is selected from the group consisting of C1-6 alkyl, —(CH2)qC3-7cycloalkyl, —(CH2)qC6 or 10aryl, and a heteroaryl, each optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, nitro, hydroxy, —COOH, —(CH2)tC3-7cycloalkyl, C2-6 alkenyl, hydroxy-C1-6alkyl, C1-6 alkyl optionally substituted with up to 5 fluoro, and C1-6 alkoxy optionally substituted with up to 5 fluoro;
- wherein R3b and R1c are each separately a hydrogen atom, or separately selected from the group consisting of C1-6 alkyl, —(CH2)qC3-7cycloalkyl, and C6 or 10 aryl, each optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, nitro, hydroxy, —(CH2)tC3-7cycloalkyl, C2-6 alkenyl, hydroxy-C1-6alkyl, phenyl, C1-6 alkyl substituted with up to 5 fluoro, and C1-6 alkoxy substituted with up to 5 fluoro;
- or R3b and R1c are taken together with the nitrogen to which they are attached to form a three- to six-membered heterocyclic ring, bonded to the parent structure through a nitrogen, and the heterocylic ring is optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, nitro, C1-6 alkyl, C1-6 alkoxy, and phenyl;
- each t is independently 0, 1 or 2;
- each q is independently 0, 1 or 2;
- and
- any bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond.
11 more elements
Dependencies are inferred from the claim text.